Alnylam Pharmaceuticals Inc.

01/21/2022 | Press release | Distributed by Public on 01/21/2022 06:33

Alnylam Presents Positive 18-Month Results from HELIOS-A Phase 3 Study of Investigational Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy